News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Penn Leaders Share Penn’s Approach to the Rapidly Changing Research Landscape
The article details Penn’s focus on sustaining research excellence, strengthening collaboration, and reshaping the University’s research enterprise to further expand its impact.
Penn Expands its Immunology Research
Penn’s newly developed seven-story facility at 3600 Civic Center Boulevard will bring together labs across disciplines to advance breakthroughs in immune health, autoimmunity, and infectious diseases.
Penn Signs Cooperative AI Advising Agreement with the Commonwealth of Pennsylvania
The University of Pennsylvania and Pennsylvania Governor Josh Shapiro’s Office of Administration signed a cooperative agreement.
Jonathan Epstein and Jim Wilson Address the Future of Life Sciences at the State of Biotech Industry Panel
They discussed the impact of federal funding cuts.
Penn Startup Showcase 2025 Shines a Spotlight on Companies Across the University
Nearly 200 people gathered at the Pennovation Center for the inaugural Penn Startup Showcase.
Ben Dibling Shares Innovation Insights on Technical.ly’s “Builders Live: The university’s changing role as startup accelerators”
The talk focuses on the impact of tech transfer on entrepreneurship and local economies.
Ben Dibling Shares Licensing and Spinout Insights with Cure
Ben discusses when publication-only or publication-plus makes sense with respect to research findings.
Dispatch Bio Developing Tumor-Agnostic Immunotherapy Targeting Solid Tumors
The technology, now in preclinical development, has the potential to overcome the limitations of traditional cancer treatments for solid tumors.
Opus Genetics Reports Positive Pediatric Data from its Clinical Trial Evaluating Investigational Gene Therapy for a Rare Eye Disorder
These findings suggest OPGx-LCA5, Opus Genetics' investigational gene augmentation therapy, could improve vision for patients previously considered untreatable.
GEMMA Biotherapeutic Announces Clinical Trial Authorization for New Gene Therapy Treatment
Its novel gene therapy for spinal muscular atrophy type 1 (SMA1) has been cleared for clinical trial in Brazil by ANVISA.